Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib.
Many cases of hypereosinophilia, formerly classified as hypereosinophilic syndrome, can now be characterized as chronic eosinophilic leukemia (CEL) based on the demonstration of characteristic genetic markers indicating clonality of hematopoiesis. Here we report on a 33-year-old male patient with central nervous system manifestations of CEL and an excellent response to low-dose imatinib (Glivec). Molecular analysis demonstrated a constitutive activation of the platelet-derived growth factor receptor-alpha (PDGFR-A) as the mechanism of responsiveness to imatinib.
Frickhofen
Norbert
N
Department of Hematology/Oncology, Dr.-Horst-Schmidt-Kliniken GmbH, Wiesbaden, Germany. norbert.frickhofen@hsk-wiesbaden.de
Märker-Hermann
Elisabeth
E
Reiter
Andreas
A
Walz
Christoph
C
Jung
Bernd
B
Bauer
Heidi
H
Hochhaus
Andreas
A
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001132:Arm; D001379:Azathioprine / Q000627:therapeutic use; D001549:Benzamides; D001921:Brain / Q000473:pathology*; D002524:Cerebellar Ataxia / Q000209:etiology; D002525:Cerebellar Cortex / Q000473:pathology; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006261:Headache / Q000209:etiology; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology* / Q000473:pathology; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017254:Leukemic Infiltration / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D008297:Male; D008569:Memory Disorders / Q000209:etiology; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors; D010291:Paresis / Q000209:etiology; D010296:Parietal Lobe / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use*; D010488:Polyarteritis Nodosa / Q000188:drug therapy / Q000209:etiology; D011241:Prednisone / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000037:antagonists & inhibitors; D012074:Remission Induction; D014717:Vertigo / Q000209:etiology; D039221:mRNA Cleavage and Polyadenylation Factors / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha; D001379:Azathioprine; D011241:Prednisone